Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic HER2-Negative Breast Carcinoma”

719 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 719 results

Post-approval studies (Phase 4)Ended earlyNCT04031885
What this trial is testing

Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 4
Early research (Phase 1)Study completedNCT01969643
What this trial is testing

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Who this might be right for
HER2 Positive Breast NeoplasmsHormone Receptor Positive Breast NeoplasmsTriple Negative Breast Neoplasms+1 more
Seagen Inc. 290
Testing effectiveness (Phase 2)Study completedNCT01653574
What this trial is testing

Famitinib Malate in HER2-negative Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Fudan University 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05979220
What this trial is testing

Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy

Who this might be right for
Breast Cancer
Shuangyue Liu 178
Testing effectiveness (Phase 2)Ended earlyNCT00959946
What this trial is testing

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Who this might be right for
Advanced Breast Cancer (Parts 1 and 2)Advanced Pancreatic Cancer (Part 1)Advanced Colorectal Cancer (Part 1)+2 more
Pfizer 32
Early research (Phase 1)Active Not RecruitingNCT05509790
What this trial is testing

LY3484356 in Chinese Participants With Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 17
Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)Ended earlyNCT00517361
What this trial is testing

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
University of Chicago 11
Testing effectiveness (Phase 2)Looking for participantsNCT06026657
What this trial is testing

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8HER2-Negative Breast Carcinoma
Margaret Gatti-Mays 42
Not applicableStudy completedNCT05054166
What this trial is testing

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

Who this might be right for
Breast CancerPI3K/AKT/mTOR Pathway MutationEverolimus
Zhejiang Cancer Hospital 14
Not applicableUnknownNCT03617341
What this trial is testing

Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer With HER2 PositiveTriple Negative Breast Cancer
Yonsei University 200
Early research (Phase 1)Ended earlyNCT04296942
What this trial is testing

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Who this might be right for
Breast CancerTriple Negative Breast CancerHER2+ Breast Cancer+2 more
National Cancer Institute (NCI) 1
Large-scale testing (Phase 3)UnknownNCT02383030
What this trial is testing

Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients

Who this might be right for
Metastatic Breast Cancer
Consorzio Oncotech 156
Testing effectiveness (Phase 2)Study completedNCT02878057
What this trial is testing

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

Who this might be right for
Breast Cancer
Peking University Cancer Hospital & Institute 30
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Large-scale testing (Phase 3)Looking for participantsNCT07207070
What this trial is testing

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd. 312
Testing effectiveness (Phase 2)WithdrawnNCT02853071
What this trial is testing

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon
Early research (Phase 1)Study completedNCT02586675
What this trial is testing

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Who this might be right for
Breast CancerBreast Cancer - FemaleBreast Cancer - Male
H. Lee Moffitt Cancer Center and Research Institute 7
Not applicableStudy completedNCT04524728
What this trial is testing

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Who this might be right for
BreastNeoplasm MalignantFemale
Istituti Clinici Scientifici Maugeri SpA 191
Large-scale testing (Phase 3)Study completedNCT01881230
What this trial is testing

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

Who this might be right for
Breast TumorBreast CancerCancer of the Breast+8 more
Celgene 191
Load More Results